PL1660482T3 - Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku - Google Patents
Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako lekuInfo
- Publication number
- PL1660482T3 PL1660482T3 PL04764411T PL04764411T PL1660482T3 PL 1660482 T3 PL1660482 T3 PL 1660482T3 PL 04764411 T PL04764411 T PL 04764411T PL 04764411 T PL04764411 T PL 04764411T PL 1660482 T3 PL1660482 T3 PL 1660482T3
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- hexyloxycarbonylamino
- benzimidazol
- phenylamino
- imino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10339862A DE10339862A1 (de) | 2003-08-29 | 2003-08-29 | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
PCT/EP2004/009432 WO2005028468A1 (de) | 2003-08-29 | 2004-08-24 | 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel |
EP04764411A EP1660482B1 (de) | 2003-08-29 | 2004-08-24 | 3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1660482T3 true PL1660482T3 (pl) | 2009-08-31 |
Family
ID=34202202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04764411T PL1660482T3 (pl) | 2003-08-29 | 2004-08-24 | Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku |
PL09153155T PL2060569T3 (pl) | 2003-08-29 | 2004-08-24 | Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09153155T PL2060569T3 (pl) | 2003-08-29 | 2004-08-24 | Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku |
Country Status (36)
Country | Link |
---|---|
US (2) | US20050234104A1 (pl) |
EP (2) | EP1660482B1 (pl) |
JP (2) | JP5348842B2 (pl) |
KR (1) | KR101331039B1 (pl) |
CN (2) | CN1845917B (pl) |
AR (2) | AR045520A1 (pl) |
AT (2) | ATE430145T1 (pl) |
AU (2) | AU2004274139B2 (pl) |
BR (1) | BRPI0413849A (pl) |
CA (2) | CA2537054C (pl) |
CO (1) | CO5660265A2 (pl) |
CY (2) | CY1109299T1 (pl) |
DE (2) | DE10339862A1 (pl) |
DK (2) | DK1660482T3 (pl) |
EA (1) | EA009736B1 (pl) |
EC (2) | ECSP066399A (pl) |
ES (2) | ES2375896T3 (pl) |
HK (2) | HK1157760A1 (pl) |
HR (2) | HRP20090311T1 (pl) |
IL (1) | IL173885A (pl) |
ME (1) | ME00340B (pl) |
MX (1) | MXPA06001959A (pl) |
MY (2) | MY145632A (pl) |
NO (2) | NO334115B1 (pl) |
NZ (2) | NZ578586A (pl) |
PE (1) | PE20050348A1 (pl) |
PL (2) | PL1660482T3 (pl) |
PT (2) | PT1660482E (pl) |
RS (2) | RS20060136A (pl) |
SG (1) | SG145734A1 (pl) |
SI (2) | SI1660482T1 (pl) |
TW (2) | TWI375674B (pl) |
UA (1) | UA85686C2 (pl) |
UY (2) | UY28493A1 (pl) |
WO (1) | WO2005028468A1 (pl) |
ZA (1) | ZA200600518B (pl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
DE102005020002A1 (de) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
DE102006054005A1 (de) * | 2006-11-16 | 2008-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
NZ586868A (en) * | 2008-03-28 | 2012-02-24 | Boehringer Ingelheim Int | Process for preparing orally administered dabigatran formulations |
AU2009272796A1 (en) * | 2008-07-14 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
CA2734804A1 (en) * | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
NZ592616A (en) | 2008-11-11 | 2013-04-26 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
WO2010130757A1 (en) | 2009-05-14 | 2010-11-18 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
HUP1000069A2 (en) | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
SI2542224T1 (sl) * | 2010-03-01 | 2014-10-30 | Ratiopharm Gmbh | Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat |
CA2792273A1 (en) | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Dabigatran etexilate-containing pharmaceutical composition |
SI2588090T1 (sl) | 2010-07-01 | 2017-06-30 | Krka, D.D., Novo Mesto | Trdne peroralne farmacevtske oblike, ki obsegajo dabigatran eteksilat in njegove farmacevtsko sprejemljive soli |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
HUE026408T2 (en) | 2010-09-27 | 2016-06-28 | Ratiopharm Gmbh | Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation |
US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
HUP1100244A2 (hu) | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Gyógyszeripari intermedierek és eljárás elõállításukra |
US20120301541A1 (en) | 2011-05-24 | 2012-11-29 | Haronsky Elina | Compressed core for pharmaceutical composition |
JP2015500853A (ja) | 2011-12-22 | 2015-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出マルチユニットペレットシステム |
US9212166B2 (en) | 2012-01-20 | 2015-12-15 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
JP2015504903A (ja) | 2012-01-24 | 2015-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の経口投与用ダビガトラン製剤 |
EP3858337A3 (en) | 2012-02-21 | 2021-09-29 | Towa Pharmaceutical Europe, S.L. | Oral pharmaceutical compositions of dabigatran etexilate |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013144971A1 (en) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
EP2834224B1 (en) | 2012-04-02 | 2018-06-06 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
EP2872499A1 (en) * | 2012-07-16 | 2015-05-20 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates |
WO2014033693A1 (en) | 2012-08-31 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate |
CN103664882A (zh) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | 结晶变体形态的达比加群酯及其制备方法和用途 |
CN103864756B (zh) * | 2012-12-11 | 2018-06-15 | 四川海思科制药有限公司 | 丁二磺酸达比加群酯及其制备方法和用途 |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN104418840A (zh) * | 2013-09-05 | 2015-03-18 | 天津汉瑞药业有限公司 | 甲磺酸达比加群酯无水化合物 |
WO2015128875A2 (en) | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
CN104892574A (zh) | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
CN108947966A (zh) * | 2014-04-04 | 2018-12-07 | 江苏天士力帝益药业有限公司 | 达比加群酯甲磺酸盐新晶型及其制备方法 |
CN105461686A (zh) * | 2014-08-25 | 2016-04-06 | 江苏豪森药业股份有限公司 | 制备高纯度甲磺酸达比加群酯晶型的方法 |
CN104825422B (zh) * | 2014-09-29 | 2017-12-12 | 普济生物科技(台州)有限公司 | 含达比加群酯甲磺酸盐的药物组合物及其制备方法 |
JP6581197B2 (ja) | 2014-12-31 | 2019-09-25 | 深▲セン▼市薬欣生物科技有限公司Shenzhen Pharmacin Co., Ltd. | 医薬組成物及びその製造方法 |
CN104725360A (zh) * | 2015-04-09 | 2015-06-24 | 重庆东得医药科技有限公司 | 一种甲磺酸达比加群酯ⅰ晶型的制备方法 |
WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
CN107778291A (zh) * | 2016-08-31 | 2018-03-09 | 亚宝药业集团股份有限公司 | 一种甲磺酸达比加群酯晶型ⅱ的制备方法 |
US20210395299A1 (en) | 2018-10-29 | 2021-12-23 | Huahai Us Inc. | Novel dipeptide compounds and uses thereof |
JP2020193184A (ja) * | 2019-05-30 | 2020-12-03 | ダイト株式会社 | ダビガトランエテキシラートメタンスルホン酸塩の形態iの製造方法 |
EP3771465A1 (en) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Pharmaceutical composition comprising dabigatran etexilate |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
CN114380793B (zh) * | 2020-10-20 | 2024-02-23 | 北京澳合药物研究院有限公司 | 一种甲磺酸达比加群酯晶型i的制备方法及其应用 |
US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
US4427468A (en) * | 1976-01-16 | 1984-01-24 | Her Majesty The Queen In Right Of Canada | Curable propellant binding systems with bonding agent combination |
DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
JPS58134033A (ja) | 1982-02-02 | 1983-08-10 | Fujisawa Pharmaceut Co Ltd | 医薬組成物 |
US4675405A (en) | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
DE4129603A1 (de) | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5416099A (en) | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
EP0653935B1 (en) | 1992-08-05 | 2002-05-08 | F.H. FAULDING & CO. LIMITED | Pelletised pharmaceutical composition |
JPH06340619A (ja) | 1993-05-03 | 1994-12-13 | Bristol Myers Squibb Co | グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤 |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
DE19752843C2 (de) | 1997-11-28 | 2003-01-09 | Byk Gulden Lomberg Chem Fab | Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol |
DE10133786A1 (de) | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
DE10209982A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
PT1485094E (pt) * | 2002-03-07 | 2012-10-09 | Boehringer Ingelheim Int | Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10245624A1 (de) * | 2002-09-30 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze |
DE10235639A1 (de) | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2004093881A2 (en) | 2003-04-24 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
US20050107438A1 (en) | 2003-09-03 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore |
EP1609784A1 (de) | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
US20060222640A1 (en) | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (de) | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
DE102005061623A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
DE102005061624A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
-
2003
- 2003-08-29 DE DE10339862A patent/DE10339862A1/de not_active Withdrawn
-
2004
- 2004-08-13 US US10/918,017 patent/US20050234104A1/en not_active Abandoned
- 2004-08-24 BR BRPI0413849-0A patent/BRPI0413849A/pt not_active Application Discontinuation
- 2004-08-24 AT AT04764411T patent/ATE430145T1/de active
- 2004-08-24 MX MXPA06001959A patent/MXPA06001959A/es active IP Right Grant
- 2004-08-24 NZ NZ578586A patent/NZ578586A/en unknown
- 2004-08-24 CA CA2537054A patent/CA2537054C/en active Active
- 2004-08-24 DE DE502004009431T patent/DE502004009431D1/de active Active
- 2004-08-24 PT PT04764411T patent/PT1660482E/pt unknown
- 2004-08-24 RS YUP-2006/0136A patent/RS20060136A/sr unknown
- 2004-08-24 SG SG200805933-9A patent/SG145734A1/en unknown
- 2004-08-24 AU AU2004274139A patent/AU2004274139B2/en active Active
- 2004-08-24 EP EP04764411A patent/EP1660482B1/de active Active
- 2004-08-24 ME MEP-2008-506A patent/ME00340B/me unknown
- 2004-08-24 PL PL04764411T patent/PL1660482T3/pl unknown
- 2004-08-24 PT PT09153155T patent/PT2060569E/pt unknown
- 2004-08-24 DK DK04764411T patent/DK1660482T3/da active
- 2004-08-24 EP EP09153155A patent/EP2060569B1/de not_active Revoked
- 2004-08-24 CA CA2749579A patent/CA2749579C/en active Active
- 2004-08-24 UA UAA200603253A patent/UA85686C2/ru unknown
- 2004-08-24 SI SI200431177T patent/SI1660482T1/sl unknown
- 2004-08-24 AT AT09153155T patent/ATE529420T1/de active
- 2004-08-24 SI SI200431794T patent/SI2060569T1/sl unknown
- 2004-08-24 ES ES09153155T patent/ES2375896T3/es active Active
- 2004-08-24 CN CN2004800249521A patent/CN1845917B/zh active Active
- 2004-08-24 EA EA200600381A patent/EA009736B1/ru not_active IP Right Cessation
- 2004-08-24 JP JP2006524316A patent/JP5348842B2/ja active Active
- 2004-08-24 DK DK09153155.8T patent/DK2060569T3/da active
- 2004-08-24 WO PCT/EP2004/009432 patent/WO2005028468A1/de active Application Filing
- 2004-08-24 PL PL09153155T patent/PL2060569T3/pl unknown
- 2004-08-24 KR KR1020067003994A patent/KR101331039B1/ko active IP Right Grant
- 2004-08-24 CN CN2011100536316A patent/CN102167695B/zh active Active
- 2004-08-24 RS RS20060136A patent/RS53370B/en unknown
- 2004-08-24 ES ES04764411T patent/ES2326654T3/es active Active
- 2004-08-24 NZ NZ545984A patent/NZ545984A/en unknown
- 2004-08-26 MY MYPI20043499A patent/MY145632A/en unknown
- 2004-08-26 MY MYPI20093734A patent/MY145696A/en unknown
- 2004-08-27 AR ARP040103089A patent/AR045520A1/es active Pending
- 2004-08-27 TW TW093125929A patent/TWI375674B/zh not_active IP Right Cessation
- 2004-08-27 TW TW100125555A patent/TWI418553B/zh not_active IP Right Cessation
- 2004-08-27 PE PE2004000824A patent/PE20050348A1/es not_active Application Discontinuation
- 2004-08-27 UY UY28493A patent/UY28493A1/es not_active Application Discontinuation
-
2006
- 2006-01-18 ZA ZA2006/00518A patent/ZA200600518B/en unknown
- 2006-02-23 IL IL173885A patent/IL173885A/en active IP Right Grant
- 2006-02-28 CO CO06019918A patent/CO5660265A2/es not_active Application Discontinuation
- 2006-03-01 EC EC2006006399A patent/ECSP066399A/es unknown
- 2006-03-28 NO NO20061420A patent/NO334115B1/no not_active IP Right Cessation
-
2007
- 2007-03-15 HK HK11112042.0A patent/HK1157760A1/xx not_active IP Right Cessation
- 2007-03-15 HK HK07102805.4A patent/HK1096682A1/xx not_active IP Right Cessation
-
2008
- 2008-01-30 US US12/022,655 patent/US7932273B2/en active Active
-
2009
- 2009-05-27 HR HR20090311T patent/HRP20090311T1/xx unknown
- 2009-07-23 CY CY20091100788T patent/CY1109299T1/el unknown
- 2009-08-28 AR ARP090103316A patent/AR073225A2/es unknown
- 2009-12-18 UY UY0001032342A patent/UY32342A/es not_active Application Discontinuation
-
2010
- 2010-04-13 AU AU2010201457A patent/AU2010201457B2/en active Active
-
2011
- 2011-05-09 JP JP2011104428A patent/JP5566332B2/ja active Active
- 2011-11-21 EC EC2011006399A patent/ECSP11006399A/es unknown
-
2012
- 2012-01-10 HR HR20120028T patent/HRP20120028T1/hr unknown
- 2012-01-11 CY CY20121100024T patent/CY1112222T1/el unknown
-
2013
- 2013-06-05 NO NO20130778A patent/NO20130778L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1660482E (pt) | Metanossulfonato de 3-[(2-{4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo e a sua utilização como medicamento | |
PL370517A1 (pl) | Doustna postać do podawania estru etylowego kwasu3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego i jego soli | |
IL211491A0 (en) | 4-(benzimidazolylmethylamino)-benzamidines | |
GB0711295D0 (en) | A method of automatic computer controlled reading of a publication | |
HK1105199A1 (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4- yl-benzothiazol-2-yl)-amide | |
IL187845A0 (en) | Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl) | |
PT1658056E (pt) | Comprimido contendo 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo ou os seus sais | |
AU157458S (en) | A portable media player | |
GB2419090B (en) | A nail clipper | |
EP1781127A4 (en) | IMPROVED BAND SUBSTRATE AND BAND THEREFROM | |
HK1101758A1 (zh) | 苯氧基烷基 硫基 -苯氧基乙酸及類似物 | |
IL181746A0 (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | |
EP1708852A4 (en) | BRAND MANAGEMENT | |
PL1705998T3 (pl) | Zastosowanie karboksypeptydazy | |
HK1111514A1 (en) | A semiconductor storage apparatus with a function of displaying information when being power down | |
GB0409735D0 (en) | Portable media player | |
GB2415947B (en) | Tape dispenser | |
GB0408158D0 (en) | Improved adhesive tape | |
FR2878149B1 (fr) | Cone court d'emmanchement de tetes femorales a grand debattement | |
GB0419546D0 (en) | A cord fastener | |
GB0401057D0 (en) | Provision of user specific information for a computer user | |
GB0410361D0 (en) | Tape dispenser | |
FR2888382B1 (fr) | Distributeur automatique d'objets | |
GB0418910D0 (en) | Novel fastener | |
GB0401456D0 (en) | Computer development 1 |